CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates a specific type of regulatory T cells linked to positive outcomes in inflammatory bowel diseases (IBD). It aims to develop innovative immunotherapy approaches using a human preclinical model to evaluate the safety and efficacy of these cells as a potential treatment for IBD.
Our project focuses on the regulatory properties of a subset of microbiota-specific TR1-like regulatory T (Treg) cells, for which we have already shown an unprecedented association with the clinical outcome of patients in various inflammatory diseases, for a therapeutic use in inflammatory bowel diseases (IBD). IBD is a disabling chronic inflammatory process that affects young individuals and causes many life-altering symptoms, and represents a risk factor for colon cancer.
Existing treatments…
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Portugal, ILHAVO
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Spain, ZARAGOZA
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
UNIVERSITY OF APPLIED SCIENCES
Germany, Kaiserslautern
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
